SCHEDULE 13D/A 0001104659-24-110566 0001953107 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 09/11/2025 false 0001736730 13463J101 CAMP4 THERAPEUTICS CORPORATION

One Kendall Square Building 1400 West, 3rd Floor Cambridge MA 02139

James P. Boylan (332) 275-5551 Enavate Sciences 106 W 56th Street, 8th Floor New York NY 10019 0001953107 N Enavate Sciences GP, LLC AF N DE 0.00 3785802.00 0.00 3785802.00 3785802.00 N 8.1 OO 0002040426 N Everest Aggregator, LP WC N DE 0.00 3785802.00 0.00 3785802.00 3785802.00 N 8.1 PN Common Stock, $0.0001 par value per share CAMP4 THERAPEUTICS CORPORATION One Kendall Square Building 1400 West, 3rd Floor Cambridge MA 02139 This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 (the "Statement") by the Reporting Entities. This Amendment No. 1 is being filed to report the dilution of the Reporting Persons' beneficial ownership in the Issuer's Common Stock and not as a result of any acquisition or disposition of securities by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. Item 4 of the Statement is amended and supplemented as follows: Effective September 9, 2025, James P. Boylan resigned from the Board of Directors of the Issuer. Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025 and (ii) 26,717,414 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on September 11, 2025. Everest LP directly holds 3,785,802 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP. Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference. No transactions with respect to the securities of the Issuer have been effected during the past sixty days by any Reporting Person. The percentage ownership reported in this amendment reflect an increase in the number of outstanding shares of the Issuer. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock. Not applicable. Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13D filed with the SEC on October 22, 2024). Enavate Sciences GP, LLC /s/ James P. Boylan 09/15/2025 Everest Aggregator, LP /s/ James P. Boylan 09/15/2025